Connect with us

Hi, what are you looking for?


Is the tumbling Dr Martens share price a bargain?

Dr Martens (LON: DOCS) share price has been in a freefall in the past few days as concerns about the company’s growth remains. The shares crashed to a low of 196p, which was its lowest level since May 22. It has plunged by more than 33% from the highest point this month.

Bootmaker faces headwinds

Dr Martens is a popular bootmaker and retailer with over 60 years in the industry. The firm manufactures some of the most popular high-fashion boots. It makes about 51% of its revenue from its Originals segment followed by Fusion and Casual. A small portion of its revenue comes from kids and accessories. 

Dr Martens stock price has been in a freefall since last week when the company published mixed results. Its revenue jumped by 18% to £418.6 million in the six months to September. Its EBITDA remained unchanged at £88.8 million while the firm’s profit after tax slipped from £48.6 million to £44.7 million.

The company’s strong growth happened because of its direct-to-consumer business, which rose by 21%. It also increased the prices of most products as inflation continued rising. By region, the company’s EMEA business grew by 9% while America had 31% growth, helped by the strong US dollar. APAC revenue rose by 9%.

Dr Martens faces significant challenges in its key markets. As inflation rises, the volume of premium shoes the firm is selling has dropped. As we wrote in this article, UK inflation surged to 11.1% in October. As a result, the firm has seen its profits retreat. It also expects that its business will remain being under pressure for a while.

The stock also plunged after the firm warned of profits in the next few quarters. Still, there are positive signs for the company. It has diversified its sourcing, with the products manufactured in China falling to 5% from 60% eight years ago. Further, the company will benefit as inflation and supply chain challenges eases.

Dr Martens share price forecast

The four-hour chart shows that the DOCS stock price has been in a strong downward trend in the past few weeks. It has managed to move below the key support levels at 205p and 203p, the lowest points at October 13 and November 24. It has moved below all moving averages.

Notably, oscillators like the Relative Strength Index (RSI) and Stochastic Oscillator have moved below the oversold level. Therefore, I suspect that the oversold shares will rebound in the coming weeks as investors buy the dip.

The post Is the tumbling Dr Martens share price a bargain? appeared first on Invezz.

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like


    Reprinted from the Future of Freedom Foundation President Biden’s campaign to banish (or maybe outlaw) political paranoia took a wallop last spring. In April,...


    Inflation appears to be on the decline. The Personal Consumption Expenditures Price Index (PCEPI), which is the Federal Reserve’s preferred measure of inflation, grew...

    Editor's Pick

    It’s already a cliché, but technology is rapidly improving. And for many businesses, it’s hard to catch up. However, it’s not just the average...

    Editor's Pick

    At Broadband World Forum 2022, Fibocom launched 5G module FG370 based on MediaTek T830 platform, aiming to empower the deployment of 5G FWA for...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2022 All Rights Reserved.